A recent trial of crizotinib in ALK-positive pediatric cancers demonstrated excellent activity in pediatric ALCL, where the NPM-ALK fusion protein is the major driver, but suboptimal activity in neuroblastoma [16]. This evidence concerns the gene ALK and neuroblastoma.